Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

@article{Horby2020DexamethasoneIH,
  title={Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report},
  author={Peter W. Horby and Wei Shen Lim and Jonathan R. Emberson and Marion M. Mafham and Jennifer L. Bell and Louise Linsell and Natalie Staplin and Christopher E. Brightling and Andrew P. Ustianowski and Einas Elmahi and Benjamin Prudon and Christopher A. Green and Timothy Felton and David R. Chadwick and Kanchan Rege and Christopher Fegan and Lucy C. Chappell and Saul N. Faust and Thomas F. Jaki and Katie Jeffery and Alan A. Montgomery and Kathryn M. Rowan and Edmund Juszczak and John Kenneth Baillie and Richard Haynes and Martin J Landray},
  journal={The New England Journal of Medicine},
  year={2020}
}
Background: Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death. Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of… 
Long-term corticosteroid therapy for patients with severe coronavirus disease 2019 (COVID-19)
TLDR
It is suggested that earlier and longer corticosteroid therapy with methylprednisolone could reduce the mortality and/or rate of ICU admission in patients with severe COVID-19, hospitalized in conventional medical ward.
Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis
TLDR
Low-dose corticosteroid treatment was associated with reduced risk of in-hospital death within 60 days in COVID-19 patients who developed ARDS and was not associated with delayed viral RNA clearance in this cohort.
Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients
TLDR
A 3-day dexamethasone course is not associated with lower 28-day mortality in critically ill COVID-19 patients, either in the entire ICU cohort or in the IMV, but not in the older IMV subgroup.
Corticosteroid use in COVID-19 pneumonia.
TLDR
Short-term low-dose corticosteroid therapy may improve clinical, radiological, laboratory outcomes in the management of COVID-19 pneumonia during the activation period without ARDS and non-septic shock and during recovery period with no satisfactory response.
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.
TLDR
In this randomized clinical trial of patients with COVID-19 and pneumonia requiring oxygen support but not admitted to the intensive care unit, TCZ did not reduce WHO-CPS scores lower than 5 at day 4 but might have reduced the risk of NIV, MV, or death by day 14, and no difference on day 28 mortality was found.
Clinical Features and Outcome of Low and High Corticosteroids in Admitted COVID-19 Patients
TLDR
Patients receiving steroids at different dosages in severe and critical COVID-19 patients who received low-dose or high-dose corticosteroid therapy compared to no steroid were more likely to have a high sequential organ failure assessment (SOFA) score.
Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study
TLDR
In patients hospitalized with COVID-19, there was no evidence of a mortality benefit associated with early initiation of corticosteroids among those on no oxygen or NC in the first 48 hours, though there was evidence of potential harm.
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
TLDR
In this randomized placebo-controlled trial in hospitalized COVID-19 pneumonia patients, tocilizumab did not improve clinical status or mortality and potential benefits in time to hospital discharge and duration of ICU stay are being investigated.
...
...

References

SHOWING 1-10 OF 62 REFERENCES
Remdesivir for the Treatment of Covid-19 — Final Report
TLDR
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia
TLDR
A short course of MP had a beneficial effect on the clinical outcome of severe COVID-19 pneumonia, decreasing the risk of the composite end point of admission to ICU, NIV or death.
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
TLDR
Corticosteroid therapy in patients with MERS was not associated with a difference in mortality after adjustment for time‐varying confounders but was associated with delayed MERS coronavirus RNA clearance.
Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia
TLDR
A systematic review and meta-analysis evaluating the effect of adjunctive corticosteroid therapy for patients hospitalized with community-acquired pneumonia and the possibility of publication bias was performed.
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
TLDR
This study conducted a retrospective multicenter study of 68 death cases and 82 discharged cases with laboratory-confirmed infection of SARS-CoV-2 and confirmed that some patients died of fulminant myocarditis, which is characterized by a rapid progress and a severe state of illness.
On the use of corticosteroids for 2019-nCoV pneumonia
Virological assessment of hospitalized patients with COVID-2019
TLDR
Detailed virological analysis of nine cases of coronavirus disease 2019 (COVID-19) provides proof of active replication of the SARS-CoV-2 virus in tissues of the upper respiratory tract.
...
...